Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Nextech3D.ai Announces First New Customer Win For its AI Powered Photography Studio (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


GREY:BIOAF - Post by User

biOasis Technologies Ord Shs > Only a corporate suit could call this merger a synergy...
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(110)
•••
Comment by prophetoffactzon Jan 17, 2023 4:56pm
79 Views
Post# 35229219

RE:RE:RE:RE:RE:RE:RE:RE:RE:Only a corporate suit could call this merger a synergy...

RE:RE:RE:RE:RE:RE:RE:RE:RE:Only a corporate suit could call this merger a synergy...There has been a material bounce in the market since the deal was put together; including in small caps. Midatech's CEO believed he could have put together an alternative financing. A second financing that eliminated the long-dated warrant could save substantial dilution. You may lose Armistice Capital, however, and have more stock in less diciplined and sophisticated hands.

"If the 20-day VWAP prior to Closing is less than $0.90, the Company may terminate the Private Placement without penalty;" Midatech news release 

G1945V wrote:
OttawaPeter wrote: True – voting no may be risky, but so is voting yes without all of the facts. DR IS the devil that we know and I don't know the other devil. From what I have read about the other guy, he's not so great either!


What I meant :

The Devil you know is the merger. A plan of action goes with the merger.

The devil you don't know is what will be left of BTI if no merger and without a plan of action and knowing the company is broke. No BTI shareholder(s), out of the 98% publically held stock, with lots of cash have stepped forward to date in defence of a "NO" vote. That's what's missing.


jmo
G1945V


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities